×
ARDT jumped +17.32% during regular trading, climbing from a $12.99 prior close to $15.24 and touching a new 52-week high. The catalyst: Ardent's Q3 2026 results beat expectations — EPS of $0.31 versus a $0.25 consensus and revenue of $1.62B versus $1.60B — and the company raised FY26 EPS guidance to $0.93–$1.18, following the Nov. 4 after-close release and Nov. 5 conference call.
Biote reported third quarter 2026 revenue of $43.3 million , down 9.6% from $48.0 million in the prior-year period. Diluted earnings per share (EPS) came in at $0.01 , beating the Zacks Consensus Estimate of a $0.05 loss, while revenue slightly missed consensus.
agilon health reported third quarter 2026 revenue of $1.52 billion , up 5.9% year over year and ahead of the roughly $1.46 billion consensus estimate. The company swung to a GAAP profit of $1.97 per diluted share , with net income of $35 million, compared with a net loss of $110 million in the prior-year quarter.
U.S. Physical Therapy reported third quarter 2026 revenue of $222.6 million, up 12.9% year over year and above the roughly $214.5 million consensus estimate. Adjusted earnings per share (EPS) came in at $0.80, exceeding analyst expectations that ranged near $0.73–$0.76.
Third quarter 2026 revenue rose 32.0% year over year to $302.3 million, coming in ahead of consensus estimates near $299 million. GAAP diluted earnings per share (EPS) was $0.26, up 52.9% from $0.17 a year earlier, while adjusted diluted EPS of $0.35 was in line with consensus.
Ardent Health reported diluted earnings per share (EPS) of $0.31 , topping the consensus estimate of $0.25 and swinging to a profit from a loss a year ago. Total revenue reached $1.62 billion , up 3.1% year over year, roughly in line with analyst expectations.
Acadia Healthcare reported third quarter 2026 revenue of $895.3 million, up 5.1% year over year and above the consensus estimate of roughly $877.8 million. Adjusted diluted earnings per share (EPS) came in at $0.60, exceeding the analyst consensus of about $0.46, though it declined from $0.72 in the prior-year quarter.
Option Care Health reported third quarter 2026 net revenue of $1.49 billion , up 4.1% year over year and modestly ahead of Wall Street consensus estimates. Adjusted diluted earnings per share (EPS) came in at $0.49 , in line with analysts' expectations and up 8.9% from the prior-year quarter.
The central $15.50 target is the average of the verified analyst price targets that sit above the current market price, not a published consensus figure. At a latest close near $13.37, reaching $15.50 would require a roughly 16% advance from the LFST stock price.
LifeStance Health (LFST) rose roughly 15% over the last 30 days, extending a multi-month advance that has lifted shares well above their mid-2026 lows. The rally builds on a strong second-quarter 2026 report, with revenue up 26% and adjusted EBITDA up 94% year over year, alongside raised full-year guidance.
Total revenue rose 50.3% year over year to $74.1 million, ahead of analyst consensus estimates. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) more than doubled to $9.6 million, with margin expanding to 13.0%.
InnovAge reported fiscal first quarter 2027 revenue of approximately $264.8 million, up roughly 12% from $236.1 million a year earlier and ahead of analyst expectations. Diluted earnings per share (EPS) came in at $0.14, comfortably above the consensus estimate of about $0.08.
COMPASS Pathways reported a third-quarter 2026 net loss of $9.83 million, sharply narrower than the $137.72 million loss in the same period a year earlier. Diluted loss per share was $0.31, versus $1.44 a year ago; the GAAP loss of $0.31 per share beat analyst consensus by $0.10.
Adjusted earnings per share (EPS, or profit allocated to each outstanding share) came in at $1.83, topping the $1.79 consensus estimate by $0.04 and rising 17.3% year over year. Net service revenue of $387.7 million grew 7.0% from a year earlier but landed slightly below the $388.70 million analysts had expected.
PACS Group reported total revenue of approximately $1.50 billion for the third quarter of 2026, up roughly 11.5% year over year and ahead of the consensus estimate of about $1.46 billion. Net income attributable to PACS Group rose about 16% year over year to $60.8 million , with reported diluted earnings per share (EPS) of $0.37 , up from $0.32 a year earlier.
Fresenius Medical Care reported third quarter 2026 revenue of €4.94 billion, up 1% year over year, while organic growth was essentially flat at 0.1%. Net income attributable to shareholders fell 42% to €160 million, pressured by roughly €108 million in one-time costs tied to the company's revised China strategy.
The central target of $2.40 is the arithmetic mean of four verified analyst price targets — $3.00, $3.00, $2.50, and $1.00 — rounded from roughly $2.38. With DCGO trading near $0.21, reaching $2.40 would require a move of more than 1,000%, an extremely large advance.
DocGo shares declined roughly 30% over the trailing 30 days, sliding from about $0.37 in early October to approximately $0.26, after touching a 52-week low near $0.21. The pullback extends a longer downtrend: the stock has fallen about 60% over the past three months.
COMPASS Pathways ( CMPS ) is advancing a late-stage psilocybin therapy toward a potential 2027 launch, while Neumora Therapeutics ( NMRA ) has pivoted to earlier-stage programs after its lead depression drug failed late-stage trials. CMPS holds a substantially larger cash position and reported positive Phase 3 data, whereas NMRA has undergone a workforce reduction and sharp analyst target cuts.
CMPS (Compass Pathways plc) is advancing a late-stage psychedelic treatment with an imminent U.S. regulatory filing, while NRSN (NeuroSense Therapeutics Ltd.) recently delayed its first marketing submission and faces a Nasdaq listing-compliance review. Compass Pathways holds a substantially stronger cash position and is building toward a potential 2027 commercial launch, whereas NeuroSense is navigating financing constraints and a pending Nasdaq Hearings Panel decision.